Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04464226 · ClinicalTrials.gov registry record · Phase 3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
A Phase 3 study of Cancer, sponsored by Bayer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 402
- Enrollment target
- 20
- Study locations
NCT04464226: Recruiting Phase 3 study of Cancer, sponsored by Bayer.
NCT04464226 is a Phase 3 study of Cancer that is actively recruiting participants, run by Bayer. The registered enrollment target is 402 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04464226, a Phase 3 study of Cancer, is actively recruiting participants, sponsored by Bayer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 402 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue in this study with darolutamide treatment on the same dosage. They will also return to the study centers for doctor's visits as often as they did in the previous study.
Conditions Studied
Interventions
- DRUG Darolutamide (Nubeqa, BAY1841788)
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- Tower Urology - Los Angeles
- VA Greater Los Angeles Healthcare System - Los Angeles
- Stanford Cancer Center Palo Alto - Palo Alto
- San Diego Clinical Trials - San Diego
- TOI Clinical Research - Whittier
Maryland
- Anne Arundel Health System - Annapolis
- Chesapeake Urology Associates - Towson - Baltimore
- Johns Hopkins Hospital - Pulmonology - Baltimore
- TidalHealth Peninsula Regional, Inc. - Oncology - Salisbury
Colorado
- VA Eastern Colorado Health Care System - Aurora
- The Urology Center Of Colorado - Denver
Florida
- Boca Raton Regional Hospital - Oncology - Boca Raton
- Advent Health Medical Group Urology - Orlando
Illinois
- Jesse Brown VA Medical Center - Cardiology - Chicago
- Illinois CancerCare - Peoria - Peoria
Alabama
- Urology Centers of Alabama, PC - Homewood
Arizona
- Ironwood Cancer and Research Centers - Chandler I - Chandler
Indiana
- First Urology PSC - Jeffersonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2020-10-20 |
| Est. Completion | 2028-06-26 |
| Phase | Phase 3 |
What NCT04464226 shows while recruiting
NCT04464226 is an interventional study that assigns participants to a tested intervention. The registered 402 participants enrollment target is mid-sized for trials with a published cap, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Darolutamide (Nubeqa, BAY1841788) is the first listed.
NCT04464226 names 20 study sites across 9 states, led by California, Maryland, Colorado.
Frequently Asked Questions
What is clinical trial NCT04464226 about?
NCT04464226 is a clinical study titled "Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer". The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previou...
What is the current status of trial NCT04464226?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 402 participants. The study started on 2020-10-20. Estimated completion is 2028-06-26.
What conditions does trial NCT04464226 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT04464226?
The interventions under investigation include: Darolutamide (Nubeqa, BAY1841788) (DRUG).
Who is sponsoring clinical trial NCT04464226?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04464226 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04464226's enrollment target sits among peer trials
402 147th of 615 higher than 469 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
RECRUITING · Phase 3
-
DOAC - Dosing Options in AntiCoagulation Prophylaxis
RECRUITING · Phase 3
-
Abatacept in Immune Checkpoint Inhibitor Myocarditis
RECRUITING · Phase 3
-
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
RECRUITING · Phase 3
-
A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients
RECRUITING · Phase 3
-
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05183763 · 402 participants · NA
Medication Adherence Program
- NCT06748222 · 402 participants · Phase 3
E-Mindfulness Approaches for Living After Breast Cancer
- NCT06896474 · 402 participants · NA
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
- NCT05647122 · 403 participants · Phase 1
First in Human Study of AZD9592 in Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI